by lythamcorp | Oct 23, 2024 | Cadrenal Therapeutics, Cadrenal Therapeutics News, Healthcare
Participation Reinforces Cadrenal’s Commitment to Innovation, Education and Improved Patient Outcomes with Anticoagulation Therapy PONTE VEDRA, Fla., Oct. 23, 2024 — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company...
by lythamcorp | Oct 23, 2024 | Energy, GSE News, GSE Systems, Technology
COLUMBIA, Md., Oct. 23, 2024 — GSE Solutions (“GSE Systems, Inc.” or “GSE”) (Nasdaq: GVP), a leader in advanced engineering solutions that supports the future of clean-energy production and decarbonization initiatives of the power...
by lythamcorp | Oct 23, 2024 | ChromaDex News, Consumer
LOS ANGELES – ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it will be participating at the 17th Annual LD Micro Main Event at the Luxe Sunset Boulevard...
by lythamcorp | Oct 22, 2024 | Energy, GSE News, GSE Systems, Technology
COLUMBIA, Md., Oct. 22, 2024 — GSE Solutions (“GSE Systems, Inc.” or “GSE”) (Nasdaq: GVP), a leader in advanced engineering solutions that supports the future of clean-energy production and decarbonization initiatives of the power...
by lythamcorp | Oct 22, 2024 | Healthcare, NeurAxis News
CARMEL, Ind., Oct. 22, 2024 — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and...